LBLeonard Charles Bailey

Leonard Charles Bailey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leonard Charles Bailey has a total of 248 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Systematic Data Fitness Assessment Improves Validity and Replicability of Research Using Real-World Data

    by Hanieh Razzaghi, Kaleigh Wieand, Annabel Pinkney, Charles Bailey

    Research replication in real-world data is essential to build trust in evidence from clinical studies. However, methods for conducting and reporting these efforts are lacking, particularly related to data fitness and limitations. We demonstrate the importance of incorporating systematic fitness testing by replicating a single-center observational study of hydroxyurea for children with severe sickle cell disease (SS/Sβ0) in a multi-institutional learning network using EHR data (PEDSnet). An AS-IS arm applied the original study’s criteria with no major data quality adjustments, while a Data Fitness Enhanced (DFE) arm used systematic data fitness assessment to inform adjustments to cohort eligibility criteria and variable definitions; both arms then replicated the original study’s primary analyses. Data quality checks in the DFE arm refined cohort accuracy and improved hydroxyurea capture, drug era computation, and hematology specialist mapping. The DFE cohort produced average treatment effects with higher face validity and greater concordance with the original study (e.g., change in ED visits: -0.44 (CI -0.60, -0.26) versus -0.36 (CI -0.57, -0.16) in the original study) than the AS-IS cohort (-0.08 (CI -0.26, 0.09)), which yielded several implausible results. These findings show that superficially plausible cohort characteristics do not guarantee valid results without transparent, systematic data fitness assessment.

  • Effects of Common Antihypertensive Class Medications on BMI z‐Score in Adolescents

    by Matthew F. Daley, Sheryl L. Rifas‐Shiman, Jessica G. Young, Joshua Petimar, Carly Prentice, L. Charles Bailey, David M. Janicke, William J. Heerman, Jason P. Block

    Background: Antihypertensive class medications are prescribed long‐term for adolescents, including for conditions other than hypertension. Evidence on weight effects is limited. Objective: To assess the weight effects of commonly prescribed antihypertensive class medications among adolescents, regardless of clinical indication for use. Methods: This retrospective study was conducted using electronic health record (EHR) data from a multi‐site US research network. The study cohort included adolescents aged 13.0–19.5 years with ≥ 1 antihypertensive class medication order during 2010–2019. Weight and height documented in the EHR were used to calculate BMI z‐scores. Inverse probability weighting with marginal structural models was used to account for selection factors and covariates. Results: Overall, 23 853 adolescents were prescribed an antihypertensive class medication, including clonidine (prescribed to n = 7491), guanfacine ( n = 6411), lisinopril ( n = 3584), propranolol ( n = 3015), spironolactone ( n = 1926), and atenolol ( n = 1426). At baseline, 13% had a hypertension diagnosis. At 12 months after medication initiation, the estimated population‐level BMI z‐score was significantly increased for propranolol (BMI z‐score 0.19 [95% CI 0.09, 0.29]) and significantly decreased for lisinopril (−0.06 [95% CI −0.10, −0.01]); clonidine, guanfacine, spironolactone, and atenolol were not associated with a significant change in BMI z‐score. Conclusions: Most antihypertensive class medications were not associated with statistically significant weight gain when prescribed to adolescents.

  • Open Access

    Beyond Missingness: Systematizing Methods for Comprehensive Data Fitness Assessment in Clinical Research

    by Hanieh Razzaghi, Kaleigh Wieand, Kimberley L Dickinson, Michael G Kahn, Jason Roy, Clair Blacketer, Dimitri A Christakis, Christopher B Forrest, Jane Greenberg, Harold P Lehmann, et al.

    Secondary use of clinical data offers unprecedented opportunities to rapidly conduct large-scale research and improve patient care. However, incomplete understanding of data quality requirements for a study often causes significant delays in executing analyses and validating results. Current practice has largely followed 2 paths. First, multi-institutional networks have developed general data quality programs, but these are typically tied to unique network characteristics and do not address study-specific requirements well. Second, models have been proposed to formalize the requirements for data fitness analyses without extending to the methods needed to meet these requirements. More recently, tools have been developed to conduct cohort-centric screening, focusing on generally applicable structural checks such as missingness or facial implausibility. These provide a first level of information but incompletely capture the fitness requirements of an analysis. In turn, investigators conduct per-study exploratory analyses, but these efforts are typically ad hoc and partially reported, which can hinder reproducible science and delay advances in patient care. Analogously to advances over the past decade in data modeling and reproducible analytics, there is a need for a more systematic, capable approach to study-specific data quality assessment (SSDQA). We discuss such a model, which guides improved SSDQA design and implementation, including metadata for consistent annotation and reporting of data quality assessment results. The model integrates theoretical principles of data quality testing with pragmatic considerations of application to clinical data, providing a consistent approach to specifying data quality assessment checks. Additionally, it proposes to regularize check application through a standard set of options. The SSDQA model builds on current practice, providing a path toward more complete, sound, and reproducible assessments. These characteristics foster multidisciplinary collaboration to identify data quality issues that, in turn, inform decisions about study design and provide important context that has a bearing on adoption of results.


  • countmaskr: Small Cell Masking Tool for One- & Two-Way Tabular Reports

    by Sahal Master, Amy Goodwin Davies, Allison Zelinski, Qiwei Shen, Charles Bailey

    Provides automated small-cell suppression for one- and two-way frequency tables. Cells falling below a user-defined frequency threshold are masked, with suppression propagated to secondary cells to prevent indirect disclosure. Designed for clinical and health administrative data, the package supports a range of tabular structures and fits into reproducible reporting pipelines, reducing manual review while applying consistent suppression rules across data sharing workflows.

  • Comparative BMI-z Changes With Initiation and Adherence to Antidepressant Medications Among Youth

    by Sheryl L. Rifas-Shiman, Jessica G. Young, Han Yu, Matthew F. Daley, William J. Heerman, David M. Janicke, W. Schuyler Jones, Kristina H. Lewis, Pi-I.D. Lin, Carly Prentice, et al.


  • A multifaceted approach to advancing data quality and fitness standards in multi-institutional networks

    by Hanieh Razzaghi, Kimberley Dickinson, Kaleigh Wieand, Samuel Boss, Hunter Weidlich, Yungui Huang, Keith Morse, Sujan Kumar Mutyala, Jyothi Priya Alekapatti Nandagopal, Karthik Viswanathan, et al.

    Objective: To construct a data quality (DQ) system that incorporates combinations of methods to evaluate data characteristics and analytic fitness across research questions for multiple uses. Materials and Methods: Drawing from experience of other data quality programs, network data extraction needs, and recurring study requirements, we developed 5 standards to guide development of a modular, multifaceted data quality system. These included annotation and documentation, ability to measure research readiness, reproducibility across networks, flexibility for the user, and interpretability to research and project teams. Implementation of checks based on these principles focused on reusability and interactive visualization of results. Results: We identified 10 check types producing over 444 check applications and deployed them in 2 multi-institutional networks. Check types span structural conformance to a data model, utility for common research needs, and study-specific customization. All check types are customizable without dependencies between them. A dashboard visualizes results, permitting adjustments based on number of data sources, need for source masking, and the user’s focus. All components can be applied as written to any data source using OMOP and are readily modified for other data models. Discussion: We have extended previous work through our novel and multifaceted approach to data quality assessment, addressing needs in both network data improvement and research usage. We developed a capable and deployable system rather than tailoring to specific use cases. Conclusion: Our novel DQ assessment system provides essential components for future standardization and collaboration to improve fitness of clinical data for intended use.


  • Open Access

    Comprehensive Fitness Assessment for Clinical Data: Standards Development and Reusable Tools (Preprint)

    by Hanieh Razzaghi, Kaleigh Wieand, Kimberley L. Dickinson, Michael G. Kahn, Jason Roy, Clair Blacketer, Dmitri A. Christakis, Christopher B. Forrest, Jane Greenberg, Harold P. Lehmann, et al.

    BACKGROUND Secondary use of clinical data offers the unprecedented opportunity to rapidly conduct large-scale research and improve patient care. However, incomplete understanding of data quality requirements for a study often causes significant delays in executing analyses and validating results. While multi-institutional networks have developed general data quality programs, they are closely tied to network characteristics and do not address many study-specific requirements. In turn, most investigators conduct per-study exploratory analyses, but these efforts are typically ad hoc and partially reported, which can hinder reproducible science and delay advances in patient care. OBJECTIVE The objectives of this study were to develop a comprehensive yet extensible model that guides study-specific data quality assessment (SSDQA) and to construct reusable data quality modules, based on the model, that can be widely disseminated and adopted. METHODS We reviewed current literature and studies, interviewed experts, and convened a group of scientists 14 times over 24 months to develop a strategy for effective and generalizable SSDQA. From this we built a model that provides guidance for improved SSDQA design and implementation, identifying reusable components and software development best practices. We created a set of executable data quality modules addressing multiple check requirements, packaged for dissemination using the R programming language. Modules include tabular output as well as high density data displays to improve the feasibility of more complete SSDQA. RESULTS The data quality model integrates theoretical principles of data quality testing with pragmatic considerations of application to clinical data. Eighteen data quality modules were specified, incorporating a wide range of theory-based check categories and practice-based check types. The nine specifications covering most common SSDQA requirements were developed as reusable software packages. Study-specific user decisions for application of a module include: (a) target data element(s), (b) single- or multi- source analyses, (c) exploratory output or statistical anomaly detection; and (d) longitudinal or cross-sectional analyses. Consistent visualizations of results are provided across multiple checks, and tabular results are available for archiving or further computation. We demonstrate that application of SSDQA modules to a cohort of pediatric patients diagnosed with sickle cell disease drawn from a multisite clinical research network produces informative results about data characteristics that may create analytic risk. CONCLUSIONS The study-specific data quality model builds on current practice, providing guidance for more complete and sound assessments. Reusable modules implementing model guidance can be readily deployed in large networks or smaller consortia, and provide detailed reporting of study-specific data quality in reproducible form. The flexibility allows investigators to tailor checks to their study requirements while retaining consistency of DQA methods. This approach fosters collaboration to identify data quality issues that can inform decisions about study design, as well as provide important context bearing on adoption of results.

  • Open Access

    Opportunities and Challenges in Using Electronic Health Record Systems to Study Postacute Sequelae of SARS-CoV-2 Infection: Insights From the NIH RECOVER Initiative

    by Hannah L Mandel, Shruti N Shah, L Charles Bailey, Thomas Carton, Yu Chen, Shari Esquenazi-Karonika, Melissa Haendel, Mady Hornig, Rainu Kaushal, Carlos R Oliveira, et al.

    The benefits and challenges of electronic health records (EHRs) as data sources for clinical and epidemiologic research have been well described. However, several factors are important to consider when using EHR data to study novel, emerging, and multifaceted conditions such as postacute sequelae of SARS-CoV-2 infection or long COVID. In this article, we present opportunities and challenges of using EHR data to improve our understanding of long COVID, based on lessons learned from the National Institutes of Health (NIH)–funded RECOVER (REsearching COVID to Enhance Recovery) Initiative, and suggest steps to maximize the usefulness of EHR data when performing long COVID research.


  • Open Access

    Systematic data quality assessment of electronic health record data to evaluate study-specific fitness: Report from the PRESERVE research study

    by Hanieh Razzaghi, Amy Goodwin Davies, Samuel Boss, H. Timothy Bunnell, Yong Chen, Elizabeth A. Chrischilles, Kimberley Dickinson, David Hanauer, Yungui Huang, K. T. Sandra Ilunga, et al.

    Study-specific data quality testing is an essential part of minimizing analytic errors, particularly for studies making secondary use of clinical data. We applied a systematic and reproducible approach for study-specific data quality testing to the analysis plan for PRESERVE, a 15-site, EHR-based observational study of chronic kidney disease in children. This approach integrated widely adopted data quality concepts with healthcare-specific evaluation methods. We implemented two rounds of data quality assessment. The first produced high-level evaluation using aggregate results from a distributed query, focused on cohort identification and main analytic requirements. The second focused on extended testing of row-level data centralized for analysis. We systematized reporting and cataloguing of data quality issues, providing institutional teams with prioritized issues for resolution. We tracked improvements and documented anomalous data for consideration during analyses. The checks we developed identified 115 and 157 data quality issues in the two rounds, involving completeness, data model conformance, cross-variable concordance, consistency, and plausibility, extending traditional data quality approaches to address more complex stratification and temporal patterns. Resolution efforts focused on higher priority issues, given finite study resources. In many cases, institutional teams were able to correct data extraction errors or obtain additional data, avoiding exclusion of 2 institutions entirely and resolving 123 other gaps. Other results identified complexities in measures of kidney function, bearing on the study’s outcome definition. Where limitations such as these are intrinsic to clinical data, the study team must account for them in conducting analyses. This study rigorously evaluated fitness of data for intended use. The framework is reusable and built on a strong theoretical underpinning. Significant data quality issues that would have otherwise delayed analyses or made data unusable were addressed. This study highlights the need for teams combining subject-matter and informatics expertise to address data quality when working with real world data.


  • Open Access

    Trends of Antihypertensive Prescription Among US Adults From 2010 to 2019 and Changes Following Treatment Guidelines: Analysis of Multicenter Electronic Health Records

    by Pi‐I Debby Lin, Sheryl Rifas‐Shiman, John Merriman, Joshua Petimar, Han Yu, Matthew F. Daley, David M. Janicke, William J. Heerman, L. Charles Bailey, Carlos Maeztu, et al.

    Background: Guidelines for the use of antihypertensives changed in 2014 and 2017. To understand the effect of these guidelines, we examined trends in antihypertensive prescriptions in the United States from 2010 to 2019 using a repeated cross‐sectional design. Methods and Results: Using electronic health records from 15 health care institutions for adults (20–85 years old) who had ≥1 antihypertensive prescription, we assessed whether (1) prescriptions of beta blockers decreased after the 2014 Eighth Joint National Committee (JNC 8) report discouraged use for first‐line treatment, (2) prescriptions for calcium channel blockers and thiazide diuretics increased among Black patients after the JNC 8 report encouraged use as first‐line therapy, and (3) prescriptions for dual therapy and fixed‐dose combination among patients with blood pressure ≥140/90 mm Hg increased after recommendations in the 2017 Hypertension Clinical Practice Guidelines. The study included 1 074 314 patients with 2 133 158 prescription episodes. After publication of the JNC 8 report, prescriptions for beta blockers decreased (3% lower in 2018–2019 compared to 2010–2014), and calcium channel blockers increased among Black patients (20% higher in 2015–2017 and 41% higher in 2018–2019, compared to 2010–2014), in accordance with guideline recommendations. However, contrary to guidelines, dual therapy and fixed‐dose combination decreased after publication of the 2017 Hypertension Clinical Practice Guidelines (9% and 11% decrease in 2018–2019 for dual therapy and fixed‐dose combination, respectively, compared to 2015–2017), and thiazide diuretics decreased among Black patients after the JNC 8 report (6% lower in 2018–2019 compared to 2010–2014). Conclusions: Adherence to guidelines on prescribing antihypertensive medication was inconsistent, presenting an opportunity for interventions to achieve better blood pressure control in the US population.